New directions for ZD1839 in the treatment of solid tumors
- 28 February 2003
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 30 (1), 49-55
- https://doi.org/10.1053/sonc.2003.50032
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Tyrosine kinase inhibitors—ZD1839 (Iressa)Current Opinion in Oncology, 2001
- EGFR and cancer prognosisEuropean Journal Of Cancer, 2001
- Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression.Oncology Reports, 2000
- Epidermal Growth Factor Receptor Tyrosine Kinase as a Target for Anticancer TherapyDrugs, 2000
- The Hallmarks of CancerCell, 2000
- The Epidermal Growth Factor Receptor and Its Inhibition in Cancer TherapyPharmacology & Therapeutics, 1999
- Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomasBritish Journal of Cancer, 1998
- EGF, TGF-a, and EGF-R in Human Colorectal AdenocarcinomaActa Oncologica, 1998
- The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, andmdr gene expression in colorectal cancerCancer, 1993
- Prognostic markers of colorectal cancer: An evaluation of DNA content, epidermal growth factor receptor, and Ki‐67Journal of Surgical Oncology, 1992